GleamWall
中文EN

PULM Pulmatrix, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%

Returns

ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$3,000
R&D expense$1,000$2,000$3,000-$3,000$8,000$14,000$19,000$6,000
SG&A expense$1.22M$1.04M$1.29M$911,000$858,000$1.53M$1.83M$1.95M
Operating income-$1.22M-$1.05M-$1.29M-$908,000-$866,000-$1.55M-$1.85M-$1.95M
Income tax———$0$0$0$0—
Net income-$1.21M-$1.04M-$1.17M-$928,000-$877,000-$1.55M-$1.81M-$1.99M
EBITDA———————-$1.95M
EPS (basic)-0.34-0.29-0.32—-0.24-0.42-0.50—
EPS (diluted)-0.34-0.29-0.32—-0.24-0.42-0.50—
Weighted avg. shares (diluted)3.65M3.65M3.65M—3.65M3.65M3.65M—
Banking
Net interest income——————$53,000$73,000
Balance sheet
Cash & equivalents$1.40M$2.17M$3.32M$4.09M$4.79M$5.83M$7.71M$9.52M
Receivables——————$16,000—
Current assets$2.36M$3.24M$4.49M$4.13M$4.97M$6.14M$8.04M$9.92M
Total assets$2.36M$3.25M$4.50M$4.14M$4.98M$6.15M$8.05M$9.94M
Current liabilities$1.02M$689,000$905,000$329,000$249,000$548,000$903,000$929,000
Total liabilities$1.02M$689,000$905,000$329,000$249,000$548,000$904,000$996,000
Shareholders' equity$1.35M$2.56M$3.59M$3.81M$4.73M$5.60M$7.15M$8.95M
Shares outstanding3.65M3.65M3.65M3.65M3.65M3.65M3.65M3.65M
Cash flow statement
Operating cash flow-$770,000-$1.11M-$1.07M-$706,000-$1.03M-$1.88M-$1.81M-$1.26M
Capital expenditure———————$0
Free cash flow———————-$1.26M
Investing cash flow———————$0
Financing cash flow$0-$50,000$1.00M—————
Depreciation & amortization———————$0
Stock-based compensation$2,000$2,000$3,000$5,000$6,000$6,000$8,000$13,000

Free plan shows the latest 8 periods; Pro shows all 54 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.